Entrada Therapeutics Inc. announced its financial results for the second quarter ending June 30, 2025. The company reported a significant drop in collaboration revenue to $2.0 million, compared to $94.7 million in the same period of 2024. This decline was primarily due to the substantial completion of collaboration research plan activities associated with VX-670. The net loss for the second quarter of 2025 was $(43.1) million, contrasting with a net income of $55.0 million reported for the same period in 2024. Research and Development (R&D) expenses increased to $37.9 million from $32.0 million in the previous year, driven by additional costs related to Duchenne muscular dystrophy (DMD) programs and higher personnel expenses. General and Administrative (G&A) expenses also rose to $10.9 million from $9.2 million due to increased personnel costs. The company's cash position stood at $354 million as of June 30, 2025, down from $420 million at the end of 2024, reflecting cash used to fund operations. Entrada Therapeutics expects its current cash reserves to support operations until the second quarter of 2027. In terms of operational updates, Entrada Therapeutics initiated multiple clinical programs targeting DMD in the U.K., EU, and U.S., including ELEVATE-44-201 and ELEVATE-45-201, with plans to initiate ELEVATE-50 and ELEVATE-51 in the near future. The leadership team has been expanded with key hires to support the company's growing pipeline.